首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells
【24h】

Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells

机译:二肽基肽酶IV调节肾小球前血管平滑肌和系膜细胞的增殖

获取原文
获取原文并翻译 | 示例

摘要

The purpose of this study was to investigate the role of dipeptidyl peptidase IV in regulating the effects of 2 of its substrates, neuropeptide Y 1-36 and peptide YY 1-36, on proliferation of and collagen production by preglomerular vascular smooth muscle and glomerular mesangial cells from spontaneously hypertensive and normotensive rats. In cells from hypertensive rats, neuropeptide Y 1-36 and peptide YY 1-36 stimulated [ 3H]-thymidine incorporation (cell proliferation index), cell number, and [ 3H]-proline incorporation (index of collagen synthesis); and sitagliptin (dipeptidyl peptidase IV inhibitor) significantly enhanced most of these effects. Neuropeptide Y 3-36 and peptide YY 3-36 (products of dipeptidyl peptidase IV) had little effect on [ 3H]-thymidine incorporation, and sitagliptin did not enhance the effects of either peptide. BIBP3226 (Y 1 receptor antagonist) blocked the effects of neuropeptide Y 1-36 and peptide YY 1-36 on [ 3H]-thymidine incorporation in the absence and presence of sitagliptin. Neuropeptide Y 1-36 and peptide YY 1-36 stimulated [ 3H]-thymidine and [ 3H]-proline incorporation and cell number in cells from normotensive rats; however, the effects were weak and mostly not affected by sitagliptin. Real-time PCR and Western blotting showed similar dipeptidyl peptidase IV mRNA and protein levels in cells from hypertensive versus normotensive rats, with greater levels in smooth muscle versus mesangial cells. Both cell types converted peptide YY 1-36 to peptide YY 3-36 in a concentration-dependent manner that was attenuated by sitagliptin, and dipeptidyl peptidase IV activity was greater in smooth muscle versus mesangial cells. In conclusion, dipeptidyl peptidase IV inhibitors might entail a risk of renal dysfunction because of abnormal proliferation of cells in the preglomerular microcirculation and glomeruli.
机译:本研究的目的是研究二肽基肽酶IV在调节其两种底物神经肽Y 1-36和肽YY 1-36对肾小球前血管平滑肌和肾小球系膜的增殖和胶原产生中的作用自发性高血压和正常血压大鼠的细胞。在高血压大鼠的细胞中,神经肽Y 1-36和肽YY 1-36刺激了[3H]-胸苷的掺入(细胞增殖指数),细胞数量和[3H]-脯氨酸的掺入(胶原蛋白合成的指数)。西他列汀(二肽基肽酶IV抑制剂)显着增强了大多数这些作用。神经肽Y 3-36和肽YY 3-36(二肽基肽酶IV的产物)对[3H]-胸腺嘧啶核苷的掺入几乎没有影响,西他列汀没有增强这两种肽的作用。在不存在西他列汀的情况下,BIBP3226(Y 1受体拮抗剂)阻断了神经肽Y 1-36和肽YY 1-36对[3H]-胸苷掺入的影响。神经肽Y 1-36和肽YY 1-36刺激了正常血压大鼠细胞中的[3H]-胸苷和[3H]-脯氨酸的掺入和细胞数;但是,这种作用微弱,并且大多数不受西他列汀的影响。实时PCR和Western印迹显示,高血压和正常血压大鼠细胞中的二肽基肽酶IV mRNA和蛋白水平相似,而平滑肌和肾小球系膜细胞中的水平更高。两种细胞类型均以浓度依赖性的方式将肽YY 1-36转换为肽YY 3-36,这被西他列汀减弱,并且在平滑肌中,二肽基肽酶IV活性比肾小球膜细胞高。总之,由于肾小球前微循环和肾小球中细胞的异常增殖,二肽基肽酶IV抑制剂可能导致肾功能不全的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号